iCAD to Participate in the LifeSci Partners 10th Annual Healthcare Corporate Access Event

Rhea-AI Summary

iCAD announced its participation in the 10th Annual LifeSci Partners Corporate Access Event from January 6-8 and 11-14, 2021. CEO Michael Klein will host meetings and participate in a panel titled Innovations in Cancer Diagnostics on January 7 at 4pm EST. The focus will be on the newly launched ProFound AI Risk software, which provides a 2-year risk estimation for breast cancer based solely on screening mammograms. Research indicates this tool effectively identifies women at high risk of a breast cancer diagnosis within two years.

New ProFound AI risk software, offering a 2-year projected risk score to be featured

NASHUA, N.H., Jan. 06, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will participate in the 10^th Annual LifeSci Partners Corporate Access Event, January 6-8 and 11-14, 2021.

Michael Klein, Chairman and CEO, will host 1x1 meetings and will participate in a panel, Innovations in Cancer Diagnostics, on Thursday, January 7^th at 4pm EST.

Mr. Klein’s focus in diagnostics will be on iCAD’s newly launched ProFound AI Risk offering. This new breast cancer screening capability is the first and only commercially available clinical decision support tool that provides an accurate 2-year risk estimation based solely on a screening mammogram. Compelling research published in Radiology concluded that the ProFound AI Risk model is effective at identifying women at high likelihood of being diagnosed with breast cancer within two years of a negative screening mammogram and in possible need of supplemental screening.

To register to listen to the presentation or to request a meeting, visit: http://lifesci.events/LifeSci2021

About iCAD, Inc.
Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions. For more information, visit www.icadmed.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995

Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. For example, when the Company discusses the potential of ProFound AI Risk and its relationship with Change Healthcare, the benefits of the Company’s products, and clinical plans and updates, it is using forward-looking statements. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company’s ability to achieve business and strategic objectives, increase sales and acceptance of products, adoption by CMS of a new payment model, and that such model will prove beneficial to the Company, which is not assured, implement expansion plans, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, uncertainty of future sales levels, protection of patents and other proprietary rights, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence of products, increased competition, to successfully defend itself in litigation matters, government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; the effects of a global pandemic, and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe,” “demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,” “anticipate,” “likely,” “seek,” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.

Contact:
Media Inquiries:
Amy Cook, iCAD
+1-925-200-2125
acook@icadmed.com

Investor Relations:
Jeremy Feffer, LifeSci Advisors
+ 1-212-915-2568
jeremy@lifesciadvisors.com

FAQ

What is ProFound AI Risk and how does it work?

ProFound AI Risk is a clinical decision support tool by iCAD that provides a 2-year risk estimation for breast cancer based solely on screening mammograms, helping identify women at high risk.

When and where will iCAD present at the LifeSci Partners Corporate Access Event?

iCAD will present at the LifeSci Partners Corporate Access Event from January 6-8 and 11-14, 2021, with a panel discussion on January 7 at 4pm EST.

How effective is the ProFound AI Risk model in identifying breast cancer risk?

Research published in Radiology indicates that the ProFound AI Risk model effectively identifies women likely to be diagnosed with breast cancer within two years of a negative screening mammogram.

Who is leading the discussion on cancer diagnostics at the event?

Michael Klein, Chairman and CEO of iCAD, will lead the discussion on innovations in cancer diagnostics during the event.

Where can I find more information about iCAD's products?

More information about iCAD's innovative cancer detection and therapy solutions can be found on their official website at www.icadmed.com.